These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 33244786)

  • 1. Adaptive enrichment trials: What are the benefits?
    Burnett T; Jennison C
    Stat Med; 2021 Feb; 40(3):690-711. PubMed ID: 33244786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bayesian Hybrid Adaptive Randomisation Design for Clinical Trials with Survival Outcomes.
    Moatti M; Chevret S; Zohar S; Rosenberger WF
    Methods Inf Med; 2016; 55(1):4-13. PubMed ID: 26404511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing subgroup selection in two-stage adaptive enrichment and umbrella designs.
    Ballarini NM; Burnett T; Jaki T; Jennison C; König F; Posch M
    Stat Med; 2021 May; 40(12):2939-2956. PubMed ID: 33783020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimized adaptive enrichment designs.
    Ondra T; Jobjörnsson S; Beckman RA; Burman CF; König F; Stallard N; Posch M
    Stat Methods Med Res; 2019 Jul; 28(7):2096-2111. PubMed ID: 29254436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian adaptive designs for multi-arm trials: an orthopaedic case study.
    Ryan EG; Lamb SE; Williamson E; Gates S
    Trials; 2020 Jan; 21(1):83. PubMed ID: 31937341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient recruitment strategies for adaptive enrichment designs with time-to-event endpoints.
    Uozumi R; Yada S; Kawaguchi A
    BMC Med Res Methodol; 2019 Jul; 19(1):159. PubMed ID: 31331277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do we need to adjust for interim analyses in a Bayesian adaptive trial design?
    Ryan EG; Brock K; Gates S; Slade D
    BMC Med Res Methodol; 2020 Jun; 20(1):150. PubMed ID: 32522284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimized adaptive enrichment designs for three-arm trials: learning which subpopulations benefit from different treatments.
    Steingrimsson JA; Betz J; Qian T; Rosenblum M
    Biostatistics; 2021 Apr; 22(2):283-297. PubMed ID: 31420983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal designs for estimating the interesting part of a dose-effect curve.
    Miller F; Guilbaud O; Dette H
    J Biopharm Stat; 2007; 17(6):1097-115. PubMed ID: 18027219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using Bayesian modeling in frequentist adaptive enrichment designs.
    Simon N; Simon R
    Biostatistics; 2018 Jan; 19(1):27-41. PubMed ID: 28520893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Group sequential designs with prospectively planned rules for subpopulation enrichment.
    Rosenblum M; Luber B; Thompson RE; Hanley D
    Stat Med; 2016 Sep; 35(21):3776-91. PubMed ID: 27076411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enrichment Bayesian design for randomized clinical trials using categorical biomarkers and a binary outcome.
    Vinnat V; Chevret S
    BMC Med Res Methodol; 2022 Feb; 22(1):54. PubMed ID: 35220954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Bayesian adaptive dose selection procedure with an overdispersed count endpoint.
    Pozzi L; Schmidli H; Gasparini M; Racine-Poon A
    Stat Med; 2013 Dec; 32(28):5008-27. PubMed ID: 24022748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing interim analysis timing for Bayesian adaptive commensurate designs.
    Wu X; Xu Y; Carlin BP
    Stat Med; 2020 Feb; 39(4):424-437. PubMed ID: 31799737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive enrichment designs for clinical trials.
    Simon N; Simon R
    Biostatistics; 2013 Sep; 14(4):613-25. PubMed ID: 23525452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bayesian adaptive clinical trial designs for respiratory medicine.
    Ryan EG; Couturier DL; Heritier S
    Respirology; 2022 Oct; 27(10):834-843. PubMed ID: 35918280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bayesian adaptive decision-theoretic designs for multi-arm multi-stage clinical trials.
    Bassi A; Berkhof J; de Jong D; van de Ven PM
    Stat Methods Med Res; 2021 Mar; 30(3):717-730. PubMed ID: 33243087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Designing Issues in Confirmatory Adaptive Population Enrichment Trials.
    Wassmer G; Dragalin V
    J Biopharm Stat; 2015; 25(4):651-69. PubMed ID: 24905739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncology.
    Jacob L; Uvarova M; Boulet S; Begaj I; Chevret S
    BMC Med Res Methodol; 2016 Jun; 16():67. PubMed ID: 27250349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sample size re-estimation in adaptive enrichment design.
    Lin R; Yang Z; Yuan Y; Yin G
    Contemp Clin Trials; 2021 Jan; 100():106216. PubMed ID: 33246098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.